ClinConnect ClinConnect Logo
Search / Trial NCT07060625

The Effect of Semi-recumbent Position on Hypoxemia After Lung Segment/Lobe Surgery

Launched by SHANGHAI PULMONARY HOSPITAL, SHANGHAI, CHINA · Jul 1, 2025

Trial Information

Current as of July 23, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

Thoracoscopic surgery is the most common surgical approach in thoracic surgery, which reduces surgical trauma and postoperative pain compared with open thoracotomy, but postoperative complications should not be overlooked, with hypoxemia being particularly prominent. Postoperative hypoxemia is highly prevalent among patients recovering from non-cardiac surgery, accounting for over one-third of all cases. Hypoxemia impairs wound healing and leads to other severe complications such as cerebral dysfunction, arrhythmia, and myocardial ischemia, all of which adversely affect postoperative recove...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 18-85 years old; Undergo thoracoscopic segment/lobectomy; American Society of Anesthesiologists (ASA) grade 1\~3
  • Exclusion Criteria:
  • Patients with mental or cognitive dysfunction who cannot communicate normally; Patients with tracheal catheters retained in ICU; Patients with cervical spondylosis, ankylosing spondylitis and other patients who cannot lift their upper body; Patients who have participated in other clinical trials; Patients who refuse to sign informed consent; Patients who have had chest surgery in the past.

About Shanghai Pulmonary Hospital, Shanghai, China

Shanghai Pulmonary Hospital, located in Shanghai, China, is a leading institution dedicated to the research and treatment of respiratory diseases. Renowned for its comprehensive clinical care and advanced research initiatives, the hospital specializes in pulmonary medicine and is committed to improving patient outcomes through innovative clinical trials. With a multidisciplinary team of experts and state-of-the-art facilities, Shanghai Pulmonary Hospital aims to contribute significantly to the global understanding and management of respiratory conditions, fostering advancements in therapeutic strategies and healthcare practices.

Locations

Shanghai, Shanghai, China

Patients applied

0 patients applied

Trial Officials

Yang Hao, postdoctor

Study Director

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported